Aurobindo Pharma Ltd. - Research Center
524804 AUROPHARMA Group (A) BSE data
Add to watchlist
| Results | |
| Statement |
P&L
|
| More |
Profit loss account
(Rs crore)
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Income | |||||
| Operating income | 12,792.28 | 11,287.14 | 15,823.68 | 13,266.48 | 12,257.89 |
| Expenses | |||||
| Material consumed | 7,009.99 | 5,981.37 | 7,425.56 | 6,692.42 | 6,362.95 |
| Manufacturing expenses | 613.92 | 477.99 | 512.34 | 520.30 | 505.96 |
| Personnel expenses | 1,641.88 | 1,600.04 | 1,735.42 | 1,561.47 | 1,362.77 |
| Selling expenses | - | - | - | - | - |
| Adminstrative expenses | 1,795.57 | 1,754.34 | 2,030.53 | 1,806.54 | 1,616.92 |
| Expenses capitalised | - | - | - | - | - |
| Cost of sales | 11,061.36 | 9,813.74 | 11,703.85 | 10,580.73 | 9,848.60 |
| Operating profit | 1,730.92 | 1,473.40 | 4,119.83 | 2,685.75 | 2,409.29 |
| Other recurring income | 433.76 | 670.99 | 589.86 | 403.37 | 199.22 |
| Adjusted PBDIT | 2,164.68 | 2,144.39 | 4,709.69 | 3,089.12 | 2,608.51 |
| Financial expenses | 114.98 | 16.94 | 28.68 | 240.94 | 230.86 |
| Depreciation | 435.35 | 415.26 | 488.00 | 470.48 | 413.03 |
| Other write offs | - | - | - | - | - |
| Adjusted PBT | 1,614.35 | 1,712.19 | 4,193.01 | 2,377.70 | 1,964.62 |
| Tax charges | 383.94 | 182.77 | 1,080.10 | 504.96 | 434.89 |
| Adjusted PAT | 1,230.41 | 1,529.42 | 3,112.91 | 1,872.74 | 1,529.73 |
| Non recurring items | 5.87 | -73.02 | -6.42 | - | - |
| Other non cash adjustments | - | - | - | - | - |
| Reported net profit | 1,236.28 | 1,456.40 | 3,106.49 | 1,872.74 | 1,529.73 |
| Earnigs before appropriation | 17,100.42 | 16,127.81 | 14,905.79 | 12,032.87 | 10,320.47 |
| Equity dividend | 439.45 | 263.67 | 234.38 | 166.12 | 132.62 |
| Preference dividend | - | - | - | - | - |
| Dividend tax | - | - | - | 9.66 | 13.86 |
| Retained earnings | 16,660.97 | 15,864.14 | 14,671.41 | 11,857.09 | 10,173.99 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis